Experience of field testing in Lebanon during the COVID-19 pandemic, January to August 2021.


Journal

BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275

Informations de publication

Date de publication:
06 2022
Historique:
received: 14 02 2022
accepted: 14 05 2022
entrez: 24 6 2022
pubmed: 25 6 2022
medline: 29 6 2022
Statut: ppublish

Résumé

Soon after detection of the first COVID-19 case in Lebanon, a testing strategy was developed aiming to early detect new cases and identify close contacts in order to implement isolation and quarantine measures, thus limiting disease transmission. Field-testing activities were initiated in March 2020, focusing on suspected cases and close contacts. The objective of this paper is to present data collected between the 1st and the 35th week of 2021 and discuss challenges and lessons learned. During the study period, testing activities were conducted in field sites covering all Lebanese districts and following a fixed schedule. Testing was provided free of charge for suspected/probable patients with COVID-19 and close contacts of positive cases. Nasopharyngeal specimens were collected and sent to designated laboratories for reverse transcription polymerase chain reaction testing. Results were received on a timely manner, within 48 hours. From the 1st to the 35th week of 2021, 1244 field-testing activities were conducted with an average of 37 testing activities per week. During this period, 71 542 samples were collected with an average of 2104 specimens per week. On average, activities covered 78% of the Lebanese districts. The average positivity rate for this period was 24% (15%-33%) in line with the virus circulation levels in the country. Timely development and implementation of a testing strategy is crucial during epidemics. The success of Lebanon's field-testing experience was mainly due to the timely adapted approach that covered all national territories, targeting all residents as well as high-risk groups in suburbs and remote areas.

Identifiants

pubmed: 35750343
pii: bmjgh-2022-008818
doi: 10.1136/bmjgh-2022-008818
pmc: PMC9234433
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Public Health Rev. 2017 Sep 8;38:22
pubmed: 29450094
J Forensic Leg Med. 2021 May;80:102179
pubmed: 33934045

Auteurs

Zeina Farah (Z)

Ministry of Public Health, Epidemiological Surveillance Program, Beirut, Lebanon zfarah.esu@gmail.com.

Nada Ghosn (N)

Ministry of Public Health, Epidemiological Surveillance Program, Beirut, Lebanon.

Tatiana Tohme (T)

Ministry of Public Health, Epidemiological Surveillance Program, Beirut, Lebanon.

Hala Abou Naja (H)

Ministry of Public Health, Epidemiological Surveillance Program, Beirut, Lebanon.

Reem Abdel Malak (R)

Ministry of Public Health, Epidemiological Surveillance Program, Beirut, Lebanon.

Hawraa Sweidan (H)

Ministry of Public Health, Epidemiological Surveillance Program, Beirut, Lebanon.

Hamad Hassan (H)

Lebanese University, Faculty of Public Health, Laboratory Sciences Department, Zahleh, Lebanon.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH